A cultured neural cell line engineered to carry human prion protein has propagated variant Creutzfeldt-Jakob disease (vCJD) prions taken from patient brain tissue, and has failed to propagate sporadic CJD isolates, according to a laboratory study by Melissa L. D. Rayner and colleagues at the Medical Research Council Prion Unit at UCL and the UCL Institute of Prion Diseases. The paper was received on 18 March 2026, accepted on 9 May 2026 and published online in the Proceedings of the National Academy of Sciences on 11 June 2026. The authors report that the same cells, carrying the same human prion protein, supported one human strain and not the other, which they take as evidence that "cellular context, rather than protein sequence alone, governs permissiveness". This is cell culture and mouse work; it involves no patients, no treatment and no diagnostic use in people.

The platform was built by silencing the cells' own prion protein and then reconstituting human prion protein, a strategy the authors describe as analogous to that used in transgenic mouse models, combined with high-throughput clonal selection. According to the paper, the cells took up brain-derived vCJD prions and sustained chronic infection; material propagated in culture then transmitted disease to humanized transgenic mice and to wild-type mice while preserving the defining biochemical and strain-specific neuropathological features of vCJD. The authors report that the system detects infection at high dilution, tolerates systematic genetic manipulation and is adaptable to automation, which is the basis of their claim that it could serve as an infectivity assay rather than only a mechanism tool.

The surveillance interest is specific to this strain. vCJD emerged after dietary exposure to bovine spongiform encephalopathy prions, and a European Centre for Disease Prevention and Control risk assessment dated 3 August 2021 records 178 vCJD cases identified in the United Kingdom, with the last reported in 2016, alongside continuing concern about blood and plasma products. Population exposure has never been fully counted: the Appendix-3 survey reported by O. Noel Gill and colleagues in Acta Neuropathologica in 2020 tested 29,516 archived appendix samples and found seven positive for abnormal prion protein, against earlier survey estimates of 237 and 493 positives per million. Genotype has long been known to matter; work published in PLOS Pathogens on 20 February 2025 by the same unit set out how the PRNP codon 129 polymorphism shapes which human strain propagates. The new report argues that a compatible sequence is not on its own sufficient.

The counterpoint sits inside the same body of work. Refractoriness in these clones does not establish that sporadic CJD cannot replicate in dividing cells: a companion PNAS paper from the unit, published online on 30 June 2026, describes a different humanized line, EKV cells, that propagates sporadic CJD prions and underpins a quantitative infectivity assay. Read together, the two reports point to the cell background as a variable in its own right, which is the mechanistic claim, not a clinical one. Neither system has been shown to work as a screening test on blood or on any other human sample, and neither speaks to prognosis or care for anyone living with a prion disease now.